Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Cancer immunotherapy shows long-term promise in lung cancer

25.04.2008
New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery -- to the same extent as chemotherapy but without the side-effects of chemotherapy.

Prof. Johan Vansteenkiste from University Hospital Gasthuisberg in Belgium described the results after 44-months follow-up from a double-blind, placebo-controlled trial in 182 patients with non-small-cell lung cancer -- the most common form of the disease.

After complete surgical resection of the tumor, patients were randomly assigned to receive either placebo injections or injections of MAGE-A3 ASCI administered over 27 months (five given at three-week intervals followed by eight given once every three months). MAGE-A3 is a tumor-specific antigen, expressed in 35-50% of non-small-cell lung cancer, but not on normal cells.

"The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3," explains Prof. Vansteenkiste. "In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells."

After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.

"Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer," says Prof. Vansteenkiste. "Postoperative chemotherapy is able to improve cure rates, but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy."

Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. "Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment." A large Phase III trial of the therapy, named MAGRIT, is now underway.

Vanessa Pavinato | alfa
Further information:
http://www.esmo.org/activities/jntconf/jntlung/

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>